Performance Evaluation of the Biological Diagnosis of HIT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

894 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-27

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

NCT01178333

Heparin Induced Thrombocytopenia

COMPLETED

The HIT-TRAP Trial

NCT00196417

Heparin-Induced Thrombocytopenia

UNKNOWN PHASE4

Heparin-Induced Thrombocytopenia Score Card Study

NCT00489437

Heparin-Induced Thrombocytopenia

COMPLETED PHASE1

EMR Tool Impact on HIT Documentation and Management

NCT05439265

Heparin Thrombocytopenia Electronic Health Records

COMPLETED

Risk Factors for Thrombosis in Immune Thrombocytopenia

NCT03820960

Immune Thrombocytopenia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heparin-induced Thrombocytopenia (HIT)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥ 18 years of age)
* Hospitalized at HUS between 01/01/2009 and 31/12/2019
* Specimen sent to the HUS Hematology Laboratory for biological diagnosis of HIT between 01/01/2009 and 31/12/2019
* Data collected by the CRPV and analyzed by the HIT multidisciplinary group in order to reach a consensus decision on the presence or absence of HIT
* Patient does not object to the reuse of his medical data for scientific research purposes.

Exclusion Criteria

* Patient for whom no test has been performed at the HUS Hematology Laboratory
* Patient for whom no data has been collected by the CRPV
* Patient for whom the HIT group could not confirm or deny the presence of HIT

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No